Pilot Trial of CRLX101 in the Treatment of Patients With Advanced HER-2 Negative Gastric, Gastroesophageal, or Esophageal Squamous or Adenocarcinoma

Trial Profile

Pilot Trial of CRLX101 in the Treatment of Patients With Advanced HER-2 Negative Gastric, Gastroesophageal, or Esophageal Squamous or Adenocarcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2016

At a glance

  • Drugs Camptothecin (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 23 Mar 2016 Results from this trial have been published in the Proceedings of the National Academy of Sciences (PNAS), according to a Cerulean Pharma media release.
    • 23 Mar 2016 Results published in a Cerulean media release.
    • 09 Nov 2015 Data was presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, according to a Cerulean Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top